Differences in biodistribution in rats injected with 99mTc-MDP preparations with different stabilizing agents

Area of Science:

• Nuclear medicine
• Radiopharmacy
• Pharmacokinetics

Background:

• Technetium-99m labeled methylene diphosphonate (MDP) is a widely used bone imaging agent.
• The stability of MDP preparations can be influenced by various stabilizing agents.
• Optimizing MDP formulation is crucial for diagnostic accuracy in bone scintigraphy.

Purpose of the Study:

• To evaluate and compare the biodistribution of four different 99mTc-MDP preparations in a preclinical rat model.
• To assess the impact of different stabilizing agents (gentisic acid, ascorbic acid, PABA) on the in vivo behavior of 99mTc-MDP.

Main Methods:

• Radiolabeling of MDP with 99mTc.
• Administration of four 99mTc-MDP preparations to young rats.
• Measurement and statistical analysis (Wilcoxon-van-Eltern test) of tissue biodistribution data.

Main Results:

• All four 99mTc-MDP preparations demonstrated acceptable biodistribution patterns in rats.
• No statistically significant differences in biodistribution were observed between MDP with gentisic acid (standard), MDP with ascorbic acid, and MDP with PABA.
• The stabilizing agents did not markedly alter the overall biodistribution profile of 99mTc-MDP.

Conclusions:

• MDP preparations stabilized with ascorbic acid and PABA exhibit comparable biodistribution to the standard gentisic acid formulation in rats.
• These findings suggest that ascorbic acid and PABA are suitable alternatives for stabilizing 99mTc-MDP, potentially offering formulation flexibility.
• Further studies may be warranted to confirm these findings in different models or clinical settings.